Omnicell, Inc. (NASDAQ:OMCL) Stock Position Decreased by US Bancorp DE

US Bancorp DE decreased its position in Omnicell, Inc. (NASDAQ:OMCL) by 61.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,498 shares of the company’s stock after selling 5,612 shares during the quarter. US Bancorp DE’s holdings in Omnicell were worth $153,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares during the last quarter. 1620 Investment Advisors Inc. boosted its holdings in shares of Omnicell by 230.1% during the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares during the period. EntryPoint Capital LLC grew its stake in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares during the last quarter. Finally, CWM LLC raised its holdings in Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after acquiring an additional 1,236 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on OMCL. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America reaffirmed a “neutral” rating and issued a $57.00 target price (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and issued a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. upped their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $50.83.

Omnicell Trading Down 2.0 %

Shares of OMCL opened at $45.67 on Friday. The stock has a market cap of $2.12 billion, a PE ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74. The stock has a 50 day simple moving average of $44.19 and a 200-day simple moving average of $36.70.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.